BioCentury | Sep 3, 2012
Clinical News

BV-NSCLC-001: Phase III started

...Bioven began an open-label, international Phase III trial to evaluate BV-NSCLC-001 plus cyclophosphamide and best supportive...
...vaccine from the Center of Molecular Immunology (Havana, Cuba). Bioven Ltd. , Aberdeen, U.K. Product: BV-NSCLC-001...
Items per page:
1 - 1 of 1